Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37737650.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2292 and PMC identifier 10873105.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 4575.
Medical subject headings
- Multiple Myeloma
- Cancer Vaccines